- recruiting
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
This study aims to understand why advanced melanoma treatments stop working for some patients. We're looking at samples from tumours and blood to find clues that predict when treatments might become less effective, helping us improve future care.
United Kingdom - recruitingPHASE1, PHASE2
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This study is testing a new drug, NUC-7738, for people with advanced cancers like solid tumours and lymphoma. It aims to see how safe the drug is, how it works in the body, and if it helps treat these cancers, sometimes combined with pembrolizumab.
United Kingdom - recruitingPHASE3
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
This study looks at treating brain tumours from melanoma or lung cancer. It compares standard treatments (like immunotherapy) plus focused radiation to standard treatments alone, aiming to find the best way to improve lives and reduce side effects.
Italy · Netherlands · Spain - active not recruitingPHASE3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
This study is looking at a new way to give medicine for advanced melanoma. We want to see if an injection under the skin works as well as the usual drip into a vein. This might make treatment easier for patients.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This study is testing different combinations of new drugs, including EOS-448, with or without standard treatments for advanced cancers like lung and head & neck cancer, and melanoma. Researchers want to see if these combinations are safe and effective.
United States · Belgium · France - active not recruitingPHASE2
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
This study looks at new treatments (Ceralasertib alone or with Durvalumab) for people with advanced melanoma that has stopped responding to standard immunotherapy. It aims to see how well they work and if they are safe.
United States · Australia · Belgium - active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
United States · Argentina · Australia - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
United Kingdom - recruitingPHASE1, PHASE2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
This study is testing a new drug, BI-1808, by itself and with another medicine, pembrolizumab (Keytruda®), for people with advanced cancers. The goal is to see how safe the new drug is, what side effects it causes, and find the right dose for future studies.
United States · Denmark · Hungary - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This study is for adults with specific cancers that have a change called BRAF V600. It's testing if two drugs, vemurafenib and cobimetinib, already used for a type of skin cancer, can help treat these other cancers. The goal is to find new treatments for patients.
United Kingdom - active not recruitingPHASE3
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
This study is looking at whether a drug called nivolumab can help prevent melanoma skin cancer from coming back in people who have had surgery to remove it. It compares nivolumab to a dummy treatment (placebo) in adults and children at high risk of their cancer returning.
United States · Australia · Austria - active not recruitingPHASE3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This study is testing a new medicine, pembrolizumab, for people in the UK with a type of skin cancer called melanoma that has been removed by surgery but is considered high-risk. It aims to see if the medicine can stop the cancer from coming back.
United States · Australia · Belgium - active not recruitingPHASE3
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.
United States · Argentina · Australia - active not recruitingPHASE2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
This study is looking for new ways to treat advanced melanoma, a type of skin cancer. It's testing combinations of new medicines (LXH254, LTT462) with existing ones (Trametinib, Ribociclib) in people whose melanoma has progressed after previous treatments. The goal is to see how well these new combinations work and if they are safe.
United States · Argentina · Australia - active not recruitingNA
VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer
This study looks into a new, keyhole surgery method (videoendoscopic radical inguinal lymphadenectomy) for penile cancer that might lead to fewer problems after the operation. It's comparing it with the traditional open surgery to see if the keyhole method is a good option for future use.
United Kingdom - recruitingPHASE3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
This study compares a new combination treatment for advanced melanoma (lifileucel plus pembrolizumab) against pembrolizumab alone. It's for people who haven't had treatment for their advanced melanoma before. The aim is to see if the new combination is more effective and safe.
United States · Australia · Belgium - recruiting
Ex VIvo DEtermiNed Cancer Therapy
This study, called EVIDENT, wants to see if we can test a tiny piece of your tumour in the lab to predict how well cancer treatments will work for you. It's for people with various solid cancers, like bladder or kidney cancer, who are having surgery or a biopsy.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This study is testing a drug called entrectinib for different cancers in adults and children. It focuses on cancers with a specific change in their cells, called ROS1 gene fusion, to see if entrectinib can be a new treatment option.
United Kingdom - active not recruitingPHASE3
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
This study looks at two drugs, encorafenib and binimetinib, for people with a specific type of high-risk skin cancer called melanoma, after surgery. It aims to see if these drugs can stop the cancer from coming back, compared to standard check-ups.
Argentina · Australia · Austria - active not recruitingPHASE3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
This study is looking at three new medicines for advanced melanoma, a type of skin cancer. It aims to see if combining these medicines helps people with melanoma that has spread and has a specific gene change called 'BRAF'.
United States · Argentina · Austria - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, TRK-950, in adults with advanced cancers like bladder, bowel, stomach, and ovarian cancer. Researchers want to find the right dose, understand if it's safe, and see how well it works when given alongside other cancer treatments.
France - ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
France - ongoing, recruitingPhase I and Phase II (Integrated)- Other
CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
This study is looking at a new way to give nivolumab, a cancer medicine, through an injection under the skin. It's for people with various advanced cancers like lung, kidney, and liver cancer, to see how the body handles the medicine and if it's safe.
Spain · Netherlands · Italy - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Study of NB003 in Patients With Advanced Malignancies
This study is testing a new medicine called NB003 for adults with certain advanced cancers, including a type of stomach/bowel cancer (Gastrointestinal stromal tumor), melanoma, and other solid tumours. It’s an early-stage study to see if the medicine is safe and how it works.
Spain · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This study looks at a new combination treatment (Vibostolimab with Pembrolizumab) for melanoma skin cancer that has a high chance of coming back. It compares this combination to an existing treatment (Pembrolizumab alone) to see if it can stop the cancer from returning.
Austria · France · Spain - active not recruitingPHASE1
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
This study looks at a new drug, MB097, combined with another treatment, Pembrolizumab, for people with melanoma that hasn't responded to previous therapy. Researchers want to see if this combination is safe and how well people tolerate it.
France · Italy · Spain - ongoing, recruitingPhase I and Phase II (Integrated)- Other
An open-label, multicenter, phase 1b/2 study of E7386 in combination with pembrolizumab in previously treated subjects with selected solid tumors
This study is testing new combinations of medicines (E7386 with pembrolizumab, and sometimes with lenvatinib) for advanced bowel cancer, melanoma, and liver cancer. Researchers want to see if these combinations are safe and if they can shrink tumors.
Spain - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
This study is looking at a new medicine, GME751, which is very similar to an existing cancer drug called Keytruda (pembrolizumab). It's for people with certain stages of skin cancer (melanoma) who need treatment after their initial cancer care. We want to see how GME751 works in the body compared to Keytruda.
Romania · Germany · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
This early-stage study is testing a new combination of medicines, AB308 and AB122, for people with several types of advanced cancer, including blood cancers and solid tumours. It aims to see if the treatment is safe and how the body reacts to it.
Spain · Poland - authorisedTherapeutic use (Phase IV)
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
This study looks at how different doses of nivolumab, a cancer medicine, work in people with melanoma or kidney cancer. It wants to find the best dose to keep the medicine effective while perhaps using less. This could make treatment easier and more affordable.
Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitors
This study, called PICASSO, is looking at a new treatment called MaaT013 for advanced melanoma. It aims to see how safe MaaT013 is when given alongside standard cancer drugs and if it can help patients live longer and respond better to treatment.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade (PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)
This study looks at a new way to treat melanoma, a type of skin cancer, using existing drugs. It combines an older chemotherapy drug (dacarbazine) with newer immunotherapy treatments (pembrolizumab, nivolumab, ipilimumab) for people whose cancer hasn't responded to immunotherapy alone. We want to see if this combination helps more people.
Germany - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy
This study is testing a new treatment, TILT-123 with avelumab, for certain skin cancers (melanoma) and head and neck cancers that haven't responded well to other treatments. It's an early-stage trial looking at safety and finding the right dose.
Finland - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone, and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or, easily injectable lymph nodes of metastatic/advanced solid tumors.
This study is testing new treatments for certain advanced cancers that have spread. We are looking at a drug called BT-001, given by itself or with pembrolizumab (a type of immunotherapy). The aim is to see if these treatments are safe and if they can control the cancer.
Belgium · France - active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
United States · Denmark · France - active not recruitingPHASE1, PHASE2
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
This study is testing a new drug, BI-1607, combined with two existing cancer drugs, pembrolizumab and ipilimumab, for advanced melanoma. Researchers want to see if this new combination is safe, effective, and helps patients whose cancer hasn't responded to other treatments.
Germany · Spain · United Kingdom - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - recruitingNA
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This study looks at adding special radiation to standard care for rare cancers that have spread a little. It wants to see if this addition helps people live longer compared to standard care alone.
Belgium · France · Germany - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - not yet recruiting
LATe TreatmENT Related Toxicity in Melanoma (LATENT)
This study looks at the long-term side effects of immunotherapy for advanced melanoma. Researchers will review existing medical records of patients who responded well to treatment for at least three years, aiming to improve future patient care and support.
United Kingdom - active not recruitingPHASE3
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is comparing two drug combinations for advanced melanoma skin cancer: fianlimab plus cemiplimab, and pembrolizumab. It aims to see which is more effective, what side effects occur, and how they affect adults and teenagers.
United States · Argentina · Australia - active not recruitingPHASE2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
This study uses a special scan called a PET/CT with a medicine called zirconium Zr 89 crefmirlimab berdoxam. It’s for people with advanced melanoma, Merkel cell cancer, kidney cancer, or lung cancer. We want to see if this scan can help predict how well immunotherapy will work for their cancer.
United States · Australia · Belgium - authorisedTherapeutic use (Phase IV)
ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.
France - authorisedTherapeutic exploratory (Phase II)
Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613
This study is looking at how well two medicines, fianlimab and cemiplimab, work together to treat a type of skin cancer called melanoma. Researchers are checking how long people live after having this combination treatment and if the cancer comes back or gets worse.
Ireland - authorisedTherapeutic exploratory (Phase II)
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY
This study looks at a new way to treat high-risk skin cancer (melanoma) using a drug called Keytruda before surgery. Researchers want to see how well Keytruda shrinks the cancer and if it's safe for patients.
France - authorisedHuman Pharmacology (Phase I)- First administration to humans
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps
This study is for adults with advanced cancer (solid tumours, including melanoma). It's an early-stage study to test a new medicine called BI 3810944. Researchers want to find the right dose and see if it could help people with certain cancers.
Belgium · Netherlands - active not recruitingPHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
This study is looking at a new combination of medicines, relatlimab and nivolumab, for advanced melanoma. It aims to see if this combination works better than nivolumab alone for melanoma that has spread or can't be removed by surgery.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France